TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3982238

Group type: EXPERIMENTAL
Intervention: Breakfast enriched in lard
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard diets excluding lard
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free choice diets
Number of subjects: 0
Study: 30712747

Group type: EXPERIMENTAL
Intervention: Gua Sha therapy (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control (n=25)
Number of subjects: 50
Study: 29501671

Group type: EXPERIMENTAL
Intervention: Montreal Imaging Stress Task (MIST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Speech task
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stroop task
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gender-related differences
Number of subjects: 60
Study: 27724922

Group type: EXPERIMENTAL
Intervention: Optimised diary
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nonoptimised diary
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both diaries
Number of subjects: 33
Study: 24438512

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells (MSC) delivered via intra-arterial injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22984506

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: Genetic variants
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: MADD
Number of subjects: 3548
Study: 19448234

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.5% ropivacaine with 0.5 microg/mL sufentanil (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.2% ropivacaine with 0.5 microg/mL sufentanil (Group 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 10 mL saline (Group 3)
Number of subjects: 45
Study: 17092845

Group type: EXPERIMENTAL
Intervention: Interpretation of spirometry and peak flow measurement by specialists
Number of subjects: 98

Group type: COMPARATOR
Intervention: General practitioners' interpretation of spirometry and peak flow measurement
Number of subjects: 98
Study: 14653084

Group type: COMPARATOR
Intervention: 10 ml saline (Group A)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: esmolol 0.5 mg/kg (Group B)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: esmolol 1.0 mg/kg (Group C)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: esmolol 1.5 mg/kg (Group D)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: esmolol 2.0 mg/kg (Group E)
Number of subjects: 175
Study: 11045293

Group type: EXPERIMENTAL
Intervention: Vancomycin (1000 mg i.v. 12 hours before procedure)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Cefazolin (1000 mg i.v. 3 hours before procedure)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (no antibiotics for at least one week before procedure)
Number of subjects: 265
Study: 9186325

Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin (50 mg)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin (80 mg)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Intravesical doxorubicin (50 mg)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control (transurethral bladder tumor resection alone)
Number of subjects: 253
Study: 1607691

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (250 mg twice a day)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Vitamin (one tablet daily)
Number of subjects: 186
Study: 4029717

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole 80 mg at 0900 and 40 mg at 1700
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole 80 mg at 0900 and 80 mg at 1700
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole 80 mg at 0900, 40 mg at 1700 and 40 mg at 0100
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31791384

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (Concerta XL) for 8 weeks, titrated over 5 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo for 8 weeks, titrated over 5 weeks
Number of subjects: 200
Study: 29188339

Group type: EXPERIMENTAL
Intervention: Best-practice diabetes care with additional evidence-based weight management programme (Counterweight-Plus)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Best-practice diabetes care alone
Number of subjects: 298
Study: 27055398

Group type: EXPERIMENTAL
Intervention: IG-IMRT
Number of subjects: 431

Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 431
Study: 24708554

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pure focal distribution of demyelination
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-focal distribution of demyelination
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mean median nerve sensory nerve conduction velocity (SNCV)
Number of subjects: 33
Study: 21970545

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg b.i.d. plus clomiphene citrate (CC) 100 mg on cycle days 3‐7
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rosiglitazone therapy
Number of subjects: 100
Study: 20304845

Group type: EXPERIMENTAL
Intervention: Autologous annuloplasty rings
Number of subjects: 100

Group type: COMPARATOR
Intervention: SJM Tailor flexible prosthesis
Number of subjects: 100
Study: 18500437

Group type: EXPERIMENTAL
Intervention: Gold bead implantation at five acupuncture points around the knee
Number of subjects: 43

Group type: COMPARATOR
Intervention: Needle insertion alone (Control)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Gold bead implantation
Number of subjects: 43
Study: 15812624

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.2 microg/kg per minute, n=15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Dobutamine (5 microg/kg per minute, n=13)
Number of subjects: 28
Study: 12356614

Group type: EXPERIMENTAL
Intervention: Acupuncture alone
Number of subjects: 141

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Education alone
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Combined acupuncture and education
Number of subjects: 141
Study: 10338443

Group type: EXPERIMENTAL
Intervention: darifenacin 5 mg t.d.s.
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 8758748

Group type: EXPERIMENTAL
Intervention: Artificial pneumothorax
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard treatments with anti-tuberculous drugs (Control)
Number of subjects: 57
Study: 1929764

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment program
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with phenelzine sulfate
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with alprazolam
Number of subjects: 65

Group type: COMPARATOR
Intervention: Pill-placebo plus instructions for self-directed exposure to phobic stimuli
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cognitive measure
Number of subjects: 65
Study: 7037163

Group type: EXPERIMENTAL
Intervention: FAMi (5‐FU, Adriamycin + mitomycin C)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: FAMe (5‐FU, Adriamycin + methyl‐CCNU)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: FIMe (6‐FU, ICRF‐159 + methyl‐CCNU)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: FMe (5‐FU + methyl‐CCNU)
Number of subjects: 181
Study: 31030995

Group type: EXPERIMENTAL
Intervention: Iclaprim 80 mg fixed dose
Number of subjects: 621

Group type: COMPARATOR
Intervention: Vancomycin 15 mg/kg administered intravenously during 2 h every 12 h for 5–14 days
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Iclaprim
Number of subjects: 621

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 621
Study: 28608434

Group type: EXPERIMENTAL
Intervention: 3D printed models of congenital cardiovascular lesions during a 20-minute lecture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard lecture on vascular rings and slings without 3D printed models
Number of subjects: 0
Study: 25612845

Group type: EXPERIMENTAL
Intervention: Fentalgon® (bilayer matrix type patch)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Durogesic SMAT (monolayer matrix type patch)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fentalgon® and Durogesic SMAT
Number of subjects: 36
Study: 24402597

Group type: EXPERIMENTAL
Intervention: Patch (13 cycles)
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Pill (6 cycles) followed by Patch (7 cycles)
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Patch
Number of subjects: 1504

Group type: COMPARATOR
Intervention: Pill
Number of subjects: 1504
Study: 21536692

Group type: COMPARATOR
Intervention: Escitalopram (up to 20 mg/day) plus placebo
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (up to 400 mg/day) plus escitalopram (up to 20 mg/day)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine (up to 300 mg/day) plus mirtazapine (up to 45 mg/day)
Number of subjects: 665
Study: 19139320

Group type: EXPERIMENTAL
Intervention: Hospital-based case manager
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 220
Study: 17762959

Group type: EXPERIMENTAL
Intervention: Fentanyl (25 mcg, titrated up to 50 mcg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Midazolam (2 mg, titrated up to 5 mg)
Number of subjects: 126
Study: 12757810

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus and Peripheral Neuropathy (DM group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (without DM)
Number of subjects: 40
Study: 10582668

Group type: EXPERIMENTAL
Intervention: Patients initially thought to have had a stroke (misdiagnosed group)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Patients correctly diagnosed with brain tumors
Number of subjects: 224
Study: 8739170

Group type: COMPARATOR
Intervention: NaF toothpaste and NaF mouthrinse
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste and mouthrinse
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste and NaF mouthrinse
Number of subjects: 150
Study: 1908864

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg q 6hr)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of indomethacin and misoprostol (200 mcg q 6hr)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Misoprostol (200 mcg q 6hr)
Number of subjects: 12
Study: 6981965

Group type: EXPERIMENTAL
Intervention: Dulcolax (bisacodyl) plus 2 L tapwater enema
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Dulcolax or castor oil or X‐Prep, each with 2 L water enema
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Water enema only or castor oil only
Number of subjects: 1435
Study: 30037692

Group type: EXPERIMENTAL
Intervention: CAD-CAM systems (group L, group iT, group C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional workflow (group K)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of digital workflow vs conventional workflow
Number of subjects: 10
Study: 28673265

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25924969

Group type: EXPERIMENTAL
Intervention: Capecitabine plus erlotinib (150 mg/day)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Gemcitabine plus erlotinib (150 mg/day)
Number of subjects: 255
Study: 23746663

Group type: EXPERIMENTAL
Intervention: Pop-up alerts
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Pharmacy intervention
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Physician alert list
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: EHR section
Number of subjects: 902
Study: 22031172

Group type: EXPERIMENTAL
Intervention: Anacetrapib co-administered with digoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 0
Study: 20380111

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprasole (continuous regimen: 5 x 40 mg in continuous infusion of 8 mg/h for 72 h)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard regimen (40 mg bolus of PPI twice daily for 3 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intensive regimen
Number of subjects: 69
Study: 17130943

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg IV (Group 1, n=40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Droperidol 1.25 mg IV (Group 2, n=40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ondansetron 2 mg IV (Group 3, n=40)
Number of subjects: 120
Study: 15446660

Group type: EXPERIMENTAL
Intervention: Sentences with punctuation (commas)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sentences without punctuation
Number of subjects: 88
Study: 10613615

Group type: EXPERIMENTAL
Intervention: 100 mg oral metoprolol tartrate twice daily for a total of nine doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control pharmacodynamic study
Number of subjects: 20
Study: 7784593

Group type: EXPERIMENTAL
Intervention: Mechanical balloon declotting
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thrombolysis with urokinase
Number of subjects: 40
Study: 1937607

Group type: EXPERIMENTAL
Intervention: High approach (n = 50, group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low approach (n = 50, group II)
Number of subjects: 100
Study: 6942150

Group type: EXPERIMENTAL
Intervention: Bilateral mandibular manipulation (BMM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chin point method (CPM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anterior guidance jig (CPJ)
Number of subjects: 30
Study: 29146543

Group type: COMPARATOR
Intervention: Interventricular delay optimisation according to QRS complex width measurement (Group 1, n=31)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Interventricular delay optimisation according to systolic dyssynchrony index (SDI) (Group 2, n=32)
Number of subjects: 63
Study: 30027615

Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 27289316

Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy (IP)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Collaborative care (CC)
Number of subjects: 135
Study: 24885201

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (10,000 IU/week)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Gargling
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600

Group type: COMPARATOR
Intervention: No Gargling
Number of subjects: 600
Study: 22466329

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo followed by Adefovir dipivoxil (ADV)
Number of subjects: 170
Study: 20097600

Group type: EXPERIMENTAL
Intervention: Email (n=40)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Fax (n=48)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Post (n=40)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Patient hand delivery (n=40)
Number of subjects: 196
Study: 18084985

Group type: EXPERIMENTAL
Intervention: Flushed epidural catheters
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unflushed epidural catheters
Number of subjects: 20
Study: 16112720

Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg, IV)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Methamphetamine (30 mg, IV)
Number of subjects: 25
Study: 12161475

Group type: COMPARATOR
Intervention: T patch alone (Testoderm TTS, 5 mg/d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Norplant II (Jadelle, 160 microg/d LNG) plus T patch
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral LNG (125 microg/d) plus T patch
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Norplant II plus T enanthate (TE) injection (100 mg/wk i.m.)
Number of subjects: 39
Study: 9895373

Group type: EXPERIMENTAL
Intervention: Gastric tonometry during exercise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gastric tonometry after revascularisation
Number of subjects: 14
Study: 7575695

Group type: EXPERIMENTAL
Intervention: 10 mg cM‐T412
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 25 mg cM‐T412
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 50 mg cM‐T412
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31971325

Group type: EXPERIMENTAL
Intervention: Mindfetalness
Number of subjects: 39865
Study: 30360898

Group type: EXPERIMENTAL
Intervention: Brief educational intervention on inhaler technique
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 97
Study: 28737861

Group type: EXPERIMENTAL
Intervention: Vitamin D levels in asthma patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Asthma control and severity in patients with vitamin D deficiency
Number of subjects: 72

Group type: COMPARATOR
Intervention: Comparison of vitamin D levels with control group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Correlation of vitamin D levels with other factors
Number of subjects: 72
Study: 26282659

Group type: EXPERIMENTAL
Intervention: 4 cups/d or more of total coffee
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: 4 cups/d or more of caffeinated coffee
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Increasing caffeine intake
Number of subjects: 953

Group type: COMPARATOR
Intervention: Nonherbal tea and decaffeinated coffee
Number of subjects: 953
Study: 24701774

Group type: EXPERIMENTAL
Intervention: Dynamic stabilization system (ligamentoplasty) placed in the segment above (group L)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No dynamic stabilization system (group S)
Number of subjects: 58
Study: 22090496

Group type: EXPERIMENTAL
Intervention: Voluntary action preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus-driven response
Number of subjects: 0
Study: 19054552

Group type: EXPERIMENTAL
Intervention: Tasimelteon 10 mg
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Tasimelteon 20 mg
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Tasimelteon 50 mg
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Tasimelteon 100 mg
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 17302061

Group type: EXPERIMENTAL
Intervention: TCM treatment beginning with Fei (SLE I formula in active stage or SLE II formula in silent period)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional Western medicinal treatment
Number of subjects: 110
Study: 15487320

Group type: EXPERIMENTAL
Intervention: Fluconazole therapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: No antifungal therapy
Number of subjects: 205
Study: 11564360

Group type: EXPERIMENTAL
Intervention: Experimental group receiving videoconferencing and Internet access in addition to standard care
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group receiving standard care
Number of subjects: 28
Study: 9782602

Group type: EXPERIMENTAL
Intervention: Vitamin E (3 x 400 mg RRR‐alpha‐Tocopherolacetat/d)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Diclofenac sodium
Number of subjects: 85
Study: 7823520

Group type: EXPERIMENTAL
Intervention: Collagen shields with vitamin A and Epidermal Growth Factor (EGF)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Collagen shields without additives
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Collagen shields with retinyl palmitate
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no collagen shields)
Number of subjects: 28
Study: 3350204

Group type: EXPERIMENTAL
Intervention: Brufen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Burana
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ibumetin
Number of subjects: 17
Study: 29491500

Group type: EXPERIMENTAL
Intervention: MyDispense
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional paper methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optional outside-of-class cases using MyDispense
Number of subjects: 0
Study: 28327893

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: MYC and BCL2 coexpression
Number of subjects: 285
Study: 26083656

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulfate (325 mg three times daily for 8 weeks)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Intravenous iron sucrose (200 mg every 2 weeks, total 1 g)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulfate
Number of subjects: 136

Group type: COMPARATOR
Intervention: Intravenous iron sucrose
Number of subjects: 136
Study: 23016924

Group type: COMPARATOR
Intervention: ABT-288 single doses (0.1, 0.3, 1, 3, 10, 20, and 40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABT-288 multiple doses (0.5, 1.5, 3, and 6 mg once-daily for 14 days in young adults)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABT-288 multiple doses (0.5, 1.5, 3, and 5 mg once-daily for 12 days in elderly subjects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABT-288 (5 mg single dose) with food
Number of subjects: 0
Study: 21118746

Group type: EXPERIMENTAL
Intervention: Test formulation of oral risperidone 2 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Reference formulation of oral risperidone 2 mg
Number of subjects: 22
Study: 18200463

Group type: EXPERIMENTAL
Intervention: Low dose diathermy technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scissors technique
Number of subjects: 40
Study: 16903819

Group type: EXPERIMENTAL
Intervention: PVP (Photovaporization of the prostate)
Number of subjects: 120

Group type: COMPARATOR
Intervention: TURP (Transurethral resection of the prostate)
Number of subjects: 120
Study: 12811310

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 7 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily for 7 days
Number of subjects: 48
Study: 10760645

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 398

Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 398